Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 180

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1B
Chunk 180
---
 impact of adopting this new accounting guidance.

129

3. Fair Value Measurement

The following table sets forth the recurring fair value of the Company’s financial assets and liabilities, allocated into the Level 1, Level 2 and Level 3 hierarchy that were measured at fair value on a recurring basis (in thousands):Fair Value Measurements as of December 31, 2024Level 1Level 2Level 3TotalAssets:Money market funds (1)$27,485 $— $— $27,485 U.S. government treasury bills12,562 — — 12,562 Commercial paper— 1,744 — 1,744 Corporate bonds— 4,261 — 4,261 Total financial assets$40,047 $6,005 $— $46,052 Fair Value Measurements as of December 31, 2023Level 1Level 2Level 3TotalAssets:Money market funds (1)$61,034 $— $— $61,034 U.S. government treasury bills19,458 — — 19,458 Commercial paper— 8,717 — 8,717 Corporate bonds (2)— 13,447 — 13,447 Government agency— 5,482 — 5,482 Total financial assets$80,492 $27,646 $— $108,138 (1)Included in cash and cash equivalents in the accompanying consolidated balance sheets.(2)Includes investments classified as cash and cash equivalent in the accompanying consolidated balance sheet.As of December 31, 2024 and 2023, all marketable securities had a contractual maturity of less than one year.

4. Short-Term Investments and Cash Equivalents

The following table summarizes the Company's short-term investments (in thousands):  As of and for Year Ended December 31, 2024Maturity          (In Years)Amortized CostUnrealized GainsUnrealized LossesFair ValueMoney market funds$27,485 $— $— $27,485 U.S. government treasury billsLess than 112,553 9 — 12,562 Commercial paperLess than 11,743 1 — 1,744 Corporate bondsLess than 14,256 5 — 4,261 Total$46,037 $15 $—